people, the middlemen in the system, that is either the pharmacy benefit managers, retailers, --lesalers, read to insurers, i am not interfacing directly with a price perspective or a paid perspective to the patient. you'reffetz: representing to us that 85% of consumers are paying less than $100. thanority are paying less $50. the reason you're having this hearing is not because the public thinks they are getting a good deal. look, i got a $600 product and i only had to pay $48. that is not why you are here. they are telling us, they are having to pay much greater numbers. ms. bresch: it is a growing minority i spoke of earlier that is being faced with the wholesale acquisition cost or more at the counter. mr. chaffetz: how do you define profit? what is profit to you? ms. bresch: the $50 per pin profits is then direct epipen cost. there is no allocation off of that. mr. chaffetz: that is not what you wrote me. less thanthis letter a week ago. here's what you said. "among other things, this profit is used to fund research and development and to maintain and improve our facilities across m

mayor more or lesales. good to see you. >> that's for nbc sports channel. let's talk about jobs. let's really get focused because we've talked about the skills gaps. i've argued that we have -- we may have a geography gap as well. good workers that can't get to where they need to be. can't sell a house. maybe the mortgage is still under water. how is louisiana? >> we have been there. >> so louisiana of course is like a great bit of the country where wage stagnation, high pockets of unemployment and poverty are still too present. there are areas that have been highly successful. look at baton rouge, have a devastating flood. some parts of that city have seen a comeback. tremendous investment. other parts, no, not much in the last 15-20 years. so louisiana is like a lot. it's a tail of two communities. >> it's such a great unique state and new orleans is great new unique city. right when you're bouncing back from something, something else happens. >> we need a break. >> you're bouncing back and not only the flooding, but as we've reported on the oil flood. the price -- we've interv

people, the middlemen in the system, that is either the pharmacy benefit managers, retailers, --lesalers, read to insurers, i am not interfacing directly with a price perspective or a paid perspective to the patient. you'reffetz: representing to us that 85% of consumers are paying less than $100. thanority are paying less $50. the reason you're having this hearing is not because the public thinks they are getting a good deal. look, i got a $600 product and i only had to pay $48. that is not why you are here. they are telling us, they are having to pay much greater numbers. ms. bresch: it is a growing minority i spoke of earlier that is being faced with the wholesale acquisition cost or more at the counter. mr. chaffetz: how do you define profit? what is profit to you? ms. bresch: the $50 per pin profits is then direct epipen cost. there is no allocation off of that. mr. chaffetz: that is not what you wrote me. less thanthis letter a week ago. here's what you said. "among other things, this profit is used to fund research and development and to maintain and improve our facilities across m